APR 27, 2016
Businesswire
Retina/Vitreous
Clearside Biomedical announced that its proprietary corticosteroid formula (Zuprata) effectively reduced the need for aflibercept by 60% in patients with macular edema associated with retinal vein occlusion (RVO).
Using Clearside’s proprietary suprachoroidal space microinjector, the steroid is delivered directly to the suprachoroidal space, limiting exposure and potential side effects to the anterior segment and other areas of the eye.
The phase 2 trial randomized 46 patients to receive either intravitreal aflibercept alone or in combination with Zuprata. Patients in the combination group required significantly fewer additional aflibercept retreatments (P=0.013) and achieved better visual recovery, with BCVA improving by 19 letters compared to 11 letters. There were no serious adverse events reported